CNS Summit 2014, Boca Raton, FL Ole Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher Missling View Poster Post navigationPreviousPrevious post:Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’sNextNext post:Anavex Upgrades to OTCQX MarketplaceRelated PostsAnavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare ConferenceSeptember 18, 2019Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeSeptember 16, 2019Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett SyndromeSeptember 4, 2019Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeJuly 31, 2019
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare ConferenceSeptember 18, 2019
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeSeptember 16, 2019
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett SyndromeSeptember 4, 2019
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeJuly 31, 2019
